课题基金 / 基金详情

Novel Approaches to Monitor the Safety and Effectiveness of Newly Marketed Diabetes Medications in Older Adults Considering Frailty and Multimorbidity

Novel Approaches to Monitor the Safety and Effectiveness of Newly Marketed Diabetes Medications in Older Adults Considering Frailty and Multimorbidity
考虑到虚弱和多重疾病,监测新上市糖尿病药物对老年人的安全性和有效性的新方法
批准号:
10066296
负责人:
Elisabetta Patorno
金额:
$16.52万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-01 至 2022-07-31

项目摘要

项目成果

Elisabetta Patorno的其他基金

相似基金

相关文献

中文摘要
翻译
本申请为临床科学家导师研究职业发展奖(K08),由
英文摘要
This application for a Mentored Clinical Scientist Research Career Development Award (K08) is submitted by Elisabetta Patorno, MD, DrPH in response to PA-16-191. Dr. Patorno is a preventive medicine physician and pharmacoepidemiologist in the Division of Pharmacoepidemiology at Brigham and Women's Hospital, and Assistant Professor of Medicine at Harvard Medical School. With a rapidly increasing US population ≥ 65 years, who use the largest proportion of medications, a better understanding of the effects of medications in older adults as used in routine care is imperative. This need is even more acute for new drugs that usually enter the market on the basis of evidence from relatively small, short, and often placebo-controlled randomized trials (RCTs), in which older patients are often underrepresented or excluded. As a result, clinicians often struggle choosing the best treatment for their older patients, particularly those with frailty and multimorbidity. Dr. Patorno is committed to a career as an independent clinical investigator, focused on advancing research for rigorously monitoring the effects of medications in older adults as treated in routine care. To achieve this, Dr. Patorno proposes a 4-year program of career development and mentored research centered on the development of a valid system for timely and high-quality evidence on new diabetes drugs in older patients specifically tailored to address the unique aspects of care in older patients such as frailty and multimorbidity. This setting of research combines the urgent need for information on the effects of over 10 new antidiabetic agents approved by the FDA in the last decade with the need for the development of novel methods for prospective drug monitoring in real-world older adults. Within the highly productive and supportive research environment of the Division of Pharmacoepidemiology, Dr. Patorno will work with an interdisciplinary team of mentors and collaborators drawn from across institutions at Harvard University that have deep expertise and national/international reputations in the specific substantive areas of her proposed training: clinical geriatrics and diabetology, methods for prospective monitoring and data mining, and health services research in older populations. The overarching objective of her mentored research is to create and implement a novel approach for the near-real-time monitoring of the comparative safety and effectiveness of new diabetes drugs in older patients as treated in routine care. This novel monitoring approach will use Medicare claims data available with a relatively short lag time, linked to electronic medical records and the Medicare Current Beneficiary Survey. The proposed work will provide timely and actionable knowledge for clinicians treating older adults, defining the net incremental value of new antidiabetic agents in older patients with frailty and multimorbidity. The knowledge gained from this work will impact several million older adults in the US, and will provide the applicant with a solid background to become an independent researcher, and ultimately a leader, in the study of medication use and outcomes in aging populations.
期刊论文(68)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/ede.0000000000000907
发表时间: 2018-11
期刊: Epidemiology (Cambridge, Mass.)
影响因子: --
作者: [Wang SV, Maro JC, Baro E, Izem R, Dashevsky I, Rogers JR, Nguyen M, Gagne JJ, Patorno E, Huybrechts KF, Major JM, Zhou E, Reidy M, Cosgrove A, Schneeweiss S, Kulldorff M]
通讯作者: Kulldorff M
DOI: 10.1161/jaha.117.008034
发表时间: 2018-03-10
期刊: Journal of the American Heart Association
影响因子: 5.4
作者: [Mayer F, Kirchmayer U, Coletta P, Agabiti N, Belleudi V, Cappai G, Di Martino M, Schneeweiss S, Davoli M, Patorno E]
通讯作者: Patorno E
DOI: 10.1161/jaha.120.016906
发表时间: 2020-09
期刊: Journal of the American Heart Association
影响因子: 5.4
作者: [Desai RJ, Levin R, Lin KJ, Patorno E]
通讯作者: Patorno E
DOI: 10.1002/edm2.237
发表时间: 2021-07
期刊: Endocrinology, diabetes & metabolism
影响因子: --
作者: [Fralick M, Kulldorff M, Redelmeier D, Wang SV, Vine S, Schneeweiss S, Patorno E]
通讯作者: Patorno E
共 31 条
    Enhancing evidence generation by linking randomized clinical trials (RCTs) to real world data (RWD)
    • 批准号:
      10250390
    • 项目类别:
    • 资助金额:
      $126.73万
    • 财政年份:
      2020
    • 负责人:
      Elisabetta Patorno
    • 依托单位:
    Enhancing evidence generation by linking randomized clinical trials (RCTs) to real world data (RWD)
    • 批准号:
      10455527
    • 项目类别:
    • 资助金额:
      $139.71万
    • 财政年份:
      2020
    • 负责人:
      Elisabetta Patorno
    • 依托单位:
    海外基金